Company HOOKIPA Pharma Inc.

Equities

HOOK

US43906K1007

Pharmaceuticals

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
0.712 USD -1.17% Intraday chart for HOOKIPA Pharma Inc. -0.13% -12.10%

Business Summary

HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel immunotherapies, based on its proprietary arenavirus platform, which is designed to mobilize and amplify targeted T cells and thereby fight or prevent serious disease. The Company's replicating and non-replicating technologies are engineered to induce durable antigen-specific CD8+ T cell responses and pathogen-neutralizing antibodies. Its oncology portfolio includes three disclosed programs, HB-200, HB-300 and HB-700, all of which use its replicating technology. HB-200 is in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) cancers in a Phase I/II clinical trial. HB-300 is in development for the treatment of prostate cancer and is in an ongoing Phase II clinical trial. HB-700 is in preclinical development for the treatment of KRAS mutated cancers, including lung, colorectal and pancreatic cancers.

Number of employees: 165

Sales per Business

USD in Million2022Weight2023Weight Delta
Pharmaceutical Products
100.0 %
14 100.0 % 20 100.0 % +41.27%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
14 100.0 % 20 100.0 % +41.27%

Managers

Managers TitleAgeSince
Chief Executive Officer 65 16-05-31
Director of Finance/CFO 54 17-03-31
Chief Tech/Sci/R&D Officer 46 12-01-31
Chief Operating Officer 56 19-10-31
Corporate Officer/Principal - -
Corporate Secretary - 17-12-31
General Counsel - 18-08-31

Members of the board

Members of the board TitleAgeSince
Chief Executive Officer 65 16-05-31
Chairman 63 17-09-30
Director of Finance/CFO 54 17-03-31
Director/Board Member 58 18-10-31
Director/Board Member 61 22-12-31
Director/Board Member 62 23-04-02
Director/Board Member 51 19-04-24
Director/Board Member 50 22-04-14

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 0 2,399,517 0 0 78.46 %
Stock B 1 96,550,590 77,635,470 ( 80.41 %) 0

Shareholders

NameEquities%Valuation
18,759,465 23.00 % 14 M $
Baker Bros. Advisors LP
9.967 %
8,128,151 9.967 % 6 M $
Artal Group SA
6.948 %
5,666,410 6.948 % 4 M $
Knoll Capital Management LP
6.766 %
5,517,385 6.766 % 4 M $
EcoR1 Capital, LLC
5.635 %
4,595,024 5.635 % 4 M $
Fidelity Management & Research Co. LLC
4.118 %
3,358,383 4.118 % 3 M $
Sofinnova Partners SAS
3.854 %
3,142,596 3.854 % 2 M $
Vanguard Global Advisers LLC
2.593 %
2,114,802 2.593 % 2 M $
Morgan Stanley Capital Services LLC
1.452 %
1,184,072 1.452 % 909 367 $
Redmile Group LLC
1.304 %
1,063,769 1.304 % 816 975 $
NameEquities%Valuation
Redmile Group LLC
78.78 %
2,346 78.78 % 1 802 $
NameEquities%Valuation
EcoR1 Capital, LLC
31.47 %
4,973 31.47 % 3 819 $

Company contact information

HOOKIPA Pharma, Inc.

350 Fifth Avenue 72nd floor, Suite 7240

10118, New York

+

http://www.hookipapharma.com
address HOOKIPA Pharma Inc.(HOOK)
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
0.712 USD
Average target price
4.89 USD
Spread / Average Target
+586.80%
Consensus